GlassScriptPhysician profile
Robert C Donlick
NPI 1023180932
$513.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $96.48 · 2021: $227 · 2022: $17.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $110.76 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $83.70 | 2019-2022 | |
| Lilly USA, LLC | $76.85 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $55.90 | 2020-2021 | |
| Novo Nordisk INC | $54.21 | 2020-2021 | |
| Amgen INC. | $32.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.56 | 2021 | |
| Pfizer INC. | $27.35 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2021 | |
| Sanofi Pasteur INC. | $13.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Donlick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.